{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:24:02Z","timestamp":1792567442745,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00198-024-07381-1","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T08:43:05Z","timestamp":1736325785000},"page":"465-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study"],"prefix":"10.1007","volume":"36","author":[{"given":"Zhenna","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Tzu-Ming","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chieh","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-7652","authenticated-orcid":false,"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"1726","key":"7381_CR1","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Int 17(1726):1733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporosis Int"},{"key":"7381_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047258","volume":"11","author":"C-W Sing","year":"2021","unstructured":"Sing C-W, Lin T-C, Bartholomew S et al (2021) Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries. BMJ Open 11:e047258. https:\/\/doi.org\/10.1136\/bmjopen-2020-047258","journal-title":"BMJ Open"},{"key":"7381_CR3","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"M LeBoff","year":"2022","unstructured":"LeBoff M, Greenspan S, Insogna K et al (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"7381_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","volume":"35","author":"C Beaudart","year":"2023","unstructured":"Beaudart C, Demonceau C, Sabico S et al (2023) Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res 35:1789\u20131806. https:\/\/doi.org\/10.1007\/s40520-023-02478-9","journal-title":"Aging Clin Exp Res"},{"key":"7381_CR5","doi-asserted-by":"publisher","first-page":"13640","DOI":"10.3390\/ijms222413640","volume":"22","author":"F Vescini","year":"2021","unstructured":"Vescini F, Chiodini I, Falchetti A et al (2021) Management of osteoporosis in men: a narrative review. Int J Mol Sci 22:13640. https:\/\/doi.org\/10.3390\/ijms222413640","journal-title":"Int J Mol Sci"},{"key":"7381_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bone.2012.11.018","volume":"53","author":"JM Kaufman","year":"2013","unstructured":"Kaufman JM, Reginster JY, Boonen S et al (2013) Treatment of osteoporosis in men. Bone 53:134\u2013144. https:\/\/doi.org\/10.1016\/j.bone.2012.11.018","journal-title":"Bone"},{"key":"7381_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.4713","volume":"28","author":"SC Shao","year":"2019","unstructured":"Shao SC, Chan YY, Kao Yang YH et al (2019) The Chang Gung Research Database\u2014a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf 28:593\u2013600. https:\/\/doi.org\/10.1002\/pds.4713","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7381_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/clep.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, Lai ECC (2019) Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol 11:349\u201358. https:\/\/doi.org\/10.2147\/clep.S196293","journal-title":"Clin Epidemiol"},{"key":"7381_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00198-021-06291-w","volume":"33","author":"EC Lai","year":"2022","unstructured":"Lai EC, Lin TC, Lange JL et al (2022) Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study. Osteoporos Int 33:1155\u20131164. https:\/\/doi.org\/10.1007\/s00198-021-06291-w","journal-title":"Osteoporos Int"},{"key":"7381_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11657-017-0375-7","volume":"12","author":"L Karlsson","year":"2017","unstructured":"Karlsson L, Mesterton J, Tepie MF, Intorcia M, Overbeek J, Strom O (2017) Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control. Arch Osteoporos 12:81. https:\/\/doi.org\/10.1007\/s11657-017-0375-7","journal-title":"Arch Osteoporos"},{"key":"7381_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/pds.3477","volume":"22","author":"F Xue","year":"2013","unstructured":"Xue F, Ma H, Stehman-Breen C et al (2013) Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia\u00ae (denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf 22:1107\u20131114. https:\/\/doi.org\/10.1002\/pds.3477","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7381_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00198-014-2624-6","volume":"25","author":"TC Lin","year":"2014","unstructured":"Lin TC, Yang CY, Kao Yang YH, Lin SJ (2014) Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int 25:1503\u20131511. https:\/\/doi.org\/10.1007\/s00198-014-2624-6","journal-title":"Osteoporos Int"},{"key":"7381_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196419","volume":"13","author":"W-Y Chiu","year":"2018","unstructured":"Chiu W-Y, Yang W-S, Chien J-Y, Lee J-J, Tsai K-S (2018) The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. PLoS ONE 13:e0196419. https:\/\/doi.org\/10.1371\/journal.pone.0196419","journal-title":"PLoS ONE"},{"key":"7381_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivariate Behav Res"},{"key":"7381_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/ede.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20:512\u2013522. https:\/\/doi.org\/10.1097\/ede.0b013e3181a663cc","journal-title":"Epidemiology"},{"key":"7381_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pds.1200","volume":"15","author":"S Schneeweiss","year":"2006","unstructured":"Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15:291\u2013303. https:\/\/doi.org\/10.1002\/pds.1200","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7381_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/nejmoa1110717","volume":"366","author":"WS Weintraub","year":"2012","unstructured":"Weintraub WS, Grau-Sepulveda MV, Weiss JM et al (2012) Comparative effectiveness of revascularization strategies. N Engl J Med 366:1467\u20131476. https:\/\/doi.org\/10.1056\/nejmoa1110717","journal-title":"N Engl J Med"},{"key":"7381_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/m16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P (2017) Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 167:268\u2013274. https:\/\/doi.org\/10.7326\/m16-2607","journal-title":"Ann Intern Med"},{"key":"7381_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s40471-020-00243-4","volume":"7","author":"X Shi","year":"2020","unstructured":"Shi X, Miao W, Tchetgen ET (2020) A selective review of negative control methods in epidemiology. Curr Epidemiol Rep 7:190\u2013202. https:\/\/doi.org\/10.1007\/s40471-020-00243-4","journal-title":"Curr Epidemiol Rep"},{"key":"7381_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581\u2013589. https:\/\/doi.org\/10.1007\/s00198-004-1780-5","journal-title":"Osteoporos Int"},{"key":"7381_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/nejmoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/nejmoa0809493","journal-title":"N Engl J Med"},{"key":"7381_CR22","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbjaerg CS, Langdahl BL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161\u20133169. https:\/\/doi.org\/10.1210\/jc.2012-1569","journal-title":"J Clin Endocrinol Metab"},{"key":"7381_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00774-020-01180-4","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Mizutani H, Tsuruya E, Fukuda R, Kuge K, Okubo N (2021) Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. J Bone Miner Metab 39:463\u2013473. https:\/\/doi.org\/10.1007\/s00774-020-01180-4","journal-title":"J Bone Miner Metab"},{"key":"7381_CR24","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/joim.13354","volume":"290","author":"SH Fu","year":"2021","unstructured":"Fu SH, Wang CY, Hung CC et al (2021) Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: a population-based cohort study. J Intern Med 290:1194\u20131205. https:\/\/doi.org\/10.1111\/joim.13354","journal-title":"J Intern Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07381-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07381-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07381-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T09:30:35Z","timestamp":1741167035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07381-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7381"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07381-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Zhenna Huang, Jeff Lange, Tzu-Chieh Lin, and Min Kim are employees and stockholders of Amgen. Edward Chia-Cheng Lai, Tzu-Chi Liao, Tzu-Ming Chuang, and Shih-Chieh Shao received the grant from Amgen to support this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocols have been approved by National Cheng Kung University (IRB No. 107\u2013008) and Chang Gung Medical Foundation (IRB No. 202102004B0) and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}}]}}